Skip to main content
. Author manuscript; available in PMC: 2019 Nov 5.
Published in final edited form as: J Immunol. 2018 Feb 5;200(6):2013–2024. doi: 10.4049/jimmunol.1700326

FIGURE 2.

FIGURE 2.

ILDR2-mFc treatment inhibits myelin epitope-specific epitope spreading in the R-EAE model. (A) On day 76 postdisease induction, five mice from each treatment group were analyzed for recall responses to spread epitopes, via injection of 10 μg of PLP178–191 in one ear and MBP84–104 into the opposite ear. The level of ear swelling was assayed 24 h postchallenge. The data are presented as the mean net ear swelling. (B) Recall responses were also carried on splenocytes. On day 76 postdisease induction, total splenocytes were collected from five representative mice from each treatment group and activated in the presence of OVA323–339, PLP139–151, PLP178–191, or MBP84–104 (20 μg/ml). Cells were pulsed with 1 mCi of tritiated thymidine at 24 h and harvested 72 h postculture set up. Cell proliferation in recall responses was also carried out using splenocytes from day-45 mice (C) or IFN-γ, IL-17, and IL-4 secretion was analyzed by LiquiChip following 72 h of culture (D–F). One representative experiment of two or three independent experiments is presented for each experimental set. *p < 0.05, **p < 0.01, ***p < 0.001 versus control Ig.